Functionalized halloysite nanotubes as a novel efficient carrier for gentamicin

•The use of HNTs silanization increases the ability to bond the intercalated drug.•The intercalated gentamicin has a prolonged release time from the silanized HNTs.•The intercalated gentamicin in HNTs is less prone to thermal degradation.•Silanized HNTs-sil/G hybrid shows a superposed antimicrobial...

Full description

Saved in:
Bibliographic Details
Published in:Materials letters 2019-05, Vol.243, p.13-16
Main Authors: Rapacz-Kmita, Alicja, Foster, Katarzyna, Mikołajczyk, Maciej, Gajek, Marcin, Stodolak-Zych, Ewa, Dudek, Magdalena
Format: Article
Language:English
Subjects:
Antibacterial activity
Antiinfectives and antibacterials
Biomaterials
Coupling agents
Drug carrier
Drug delivery systems
E coli
Grafting
Halloysite nanotubes
Materials science
Nanoparticles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•The use of HNTs silanization increases the ability to bond the intercalated drug.•The intercalated gentamicin has a prolonged release time from the silanized HNTs.•The intercalated gentamicin in HNTs is less prone to thermal degradation.•Silanized HNTs-sil/G hybrid shows a superposed antimicrobial activity. The halloysite/3-Aminopropyltrietthoxysilane/gentamicin hybrid was obtained as a novel carrier for sustained drug release in antimicrobial treatment. The nanocarrier was prepared by functionalizing the halloysite surface with the 3-Aminopropyltrietthoxysilane, which was introduced into the system as a coupling agent to efficiently bond the drug in to the halloysite lumen. The interaction between gentamicin, silane and halloysite as well as the antimicrobial susceptibility against E. coli, S. aureus and S. epidermidis were investigated. The results indicate that silane grafting combined with intercalation of gentamicin resulted in efficient drug bonding to the inner surface of halloysite and ultimately extended drug release from the tested hybrid.
ISSN:0167-577X
1873-4979
DOI:10.1016/j.matlet.2019.02.015